Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedFeb 21, 2026
DataAggregated Company Financials
Companies9
  • 7D1.7%
  • 3M18.5%
  • 1Y27.9%
  • YTD13.2%

The Pharma industry is up 2.3% in the last week, with Roche Holding up 2.2%. This means that the industry has gained 29% over the past year. Earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 21 Feb 2026CHF 607.2bCHF 119.8bCHF 24.3b37.2x24.9x5.1x
Mon, 19 Jan 2026CHF 591.2bCHF 121.6bCHF 21.6b36.8x27.3x4.9x
Wed, 17 Dec 2025CHF 549.1bCHF 121.1bCHF 21.5b33.2x25.5x4.5x
Fri, 14 Nov 2025CHF 516.2bCHF 120.8bCHF 21.4b33.4x24.1x4.3x
Sun, 12 Oct 2025CHF 513.0bCHF 120.5bCHF 21.0b33.3x24.4x4.3x
Tue, 09 Sep 2025CHF 490.4bCHF 119.9bCHF 20.9b31.3x23.5x4.1x
Thu, 07 Aug 2025CHF 447.0bCHF 120.7bCHF 20.9b22.4x21.4x3.7x
Sat, 05 Jul 2025CHF 452.9bCHF 117.1bCHF 18.9b25x24x3.9x
Mon, 02 Jun 2025CHF 445.5bCHF 119.0bCHF 19.3b25.5x23.1x3.7x
Wed, 30 Apr 2025CHF 436.5bCHF 119.1bCHF 19.3b25.8x22.7x3.7x
Fri, 28 Mar 2025CHF 464.5bCHF 121.7bCHF 19.2b28.3x24.2x3.8x
Sun, 23 Feb 2025CHF 482.7bCHF 122.3bCHF 19.1b23.4x25.3x3.9x
Tue, 21 Jan 2025CHF 440.4bCHF 119.5bCHF 21.4b18.4x20.6x3.7x
Thu, 19 Dec 2024CHF 424.0bCHF 118.6bCHF 21.3b17.9x20x3.6x
Sat, 16 Nov 2024CHF 430.5bCHF 118.3bCHF 21.2b18.4x20.3x3.6x
Mon, 14 Oct 2024CHF 457.6bCHF 115.3bCHF 19.4b21.7x23.6x4x
Wed, 11 Sep 2024CHF 455.3bCHF 114.7bCHF 19.3b21.8x23.6x4x
Fri, 09 Aug 2024CHF 453.9bCHF 115.8bCHF 19.5b22.3x23.2x3.9x
Sun, 07 Jul 2024CHF 430.8bCHF 116.2bCHF 19.7b34.1x21.8x3.7x
Tue, 04 Jun 2024CHF 412.1bCHF 116.3bCHF 19.8b41.6x20.8x3.5x
Thu, 02 May 2024CHF 393.9bCHF 114.0bCHF 20.0b38.4x19.6x3.5x
Sat, 30 Mar 2024CHF 392.0bCHF 111.9bCHF 19.4b38.1x20.2x3.5x
Mon, 26 Feb 2024CHF 390.6bCHF 110.4bCHF 19.7b24.8x19.8x3.5x
Wed, 24 Jan 2024CHF 413.2bCHF 120.6bCHF 18.8b27.1x22x3.4x
Fri, 22 Dec 2023CHF 394.0bCHF 119.8bCHF 18.7b24.8x21.1x3.3x
Sun, 19 Nov 2023CHF 386.7bCHF 121.6bCHF 18.9b23.9x20.4x3.2x
Tue, 17 Oct 2023CHF 407.4bCHF 121.5bCHF 18.6b26.2x21.9x3.4x
Thu, 14 Sep 2023CHF 404.7bCHF 112.5bCHF 18.0b47x22.5x3.6x
Sat, 12 Aug 2023CHF 413.3bCHF 111.6bCHF 17.9b48.5x23.1x3.7x
Mon, 10 Jul 2023CHF 403.5bCHF 114.8bCHF 18.8b35.1x21.4x3.5x
Wed, 07 Jun 2023CHF 437.2bCHF 115.7bCHF 19.0b37.9x23.1x3.8x
Fri, 05 May 2023CHF 434.0bCHF 114.6bCHF 18.8b42.3x23.1x3.8x
Sun, 02 Apr 2023CHF 412.5bCHF 115.8bCHF 18.9b42x21.8x3.6x
Tue, 28 Feb 2023CHF 402.9bCHF 116.9bCHF 19.1b27.4x21.1x3.4x
Price to Earnings Ratio

21.1x


Total Market Cap: CHF 402.9bTotal Earnings: CHF 19.1bTotal Revenue: CHF 116.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are optimistic on the Swiss Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 25.0x which is higher than its 3-year average PE of 22.5x.
  • The 3-year average PS ratio of 3.8x is lower than the industry's current PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 8.4% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.72%
Healthcare1.68%
Pharma1.69%
Pharma1.69%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROG Roche HoldingCHF 367.802.2%
+CHF 6.2b		23.3%PE22.7x
NOVN NovartisCHF 126.461.1%
+CHF 2.5b		28.8%PE22.2x
SDZ Sandoz GroupCHF 67.042.1%
+CHF 603.0m		60.5%PE164x
GALD Galderma GroupCHF 154.201.3%
+CHF 474.8m		35.6%PE124.9x
DESN Dottikon ES HoldingCHF 348.003.9%
+CHF 179.7m		64.2%PE39.8x

Latest News

SDZ
CHF 67.04
Sandoz Group
7D
2.1%
1Y
60.5%
ROG
CHF 367.80
Roche Holding
7D
2.2%
1Y
23.3%
NOVN
CHF 126.46
Novartis
7D
1.1%
1Y
28.8%
BIOV
CHF 23.60
BioVersys
7D
1.7%
1Y
-34.9%
NWRN
CHF 19.26
Newron Pharmaceuticals
7D
-3.2%
1Y
86.6%
GALD
CHF 154.20
Galderma Group
7D
1.3%
1Y
35.6%

GALD: Higher CHF 195 Outlook Will Support Future Re Rating Conviction

Analysts have raised their price target on Galderma Group to CHF 195 from CHF 155, reflecting updated views on revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent research points to a more constructive stance on Galderma Group, with bullish analysts lifting their price targets and expressing increased confidence in the company’s execution and valuation framework.
COPN
CHF 119.20
Cosmo Pharmaceuticals
7D
3.3%
1Y
74.8%

COPN: EU Acne Approval And Share Placement Will Support Bullish Outlook

Analysts now set their price target for Cosmo Pharmaceuticals closer to €150, up from about €102, citing updated assumptions for revenue growth, profit margins and future P/E, which feed into a higher fair value estimate. What's in the News Cosmo Pharmaceuticals completed a private placement of 937,086 treasury shares, representing 5.3% of its outstanding shares, with a single institutional investor on February 3, 2026.
DESN
CHF 348.00
Dottikon ES Holding
7D
3.9%
1Y
64.2%
ADXN
CHF 0.048
Addex Therapeutics
7D
-3.2%
1Y
-14.6%
CURN
CHF 17.40
Curatis Holding
7D
1.2%
1Y
54.7%